Tourmaline Bio, Inc. Reports Third Quarter Financial Results [Yahoo! Finance]
Tourmaline Bio, Inc. (TRML)
Company Research
Source: Yahoo! Finance
Tourmaline Bio, Inc. is a clinical-stage biotechnology company focused on developing transformative treatments for immune and inflammatory diseases, primarily through its lead candidate pacibekitug, a monoclonal antibody targeting interleukin-6. In its latest earnings report, the company disclosed significant financial movements, with a noticeable increase in short-term investments and a reduction in cash due to strategic financing activities. The report highlighted a net loss of $20.2 million for the third quarter of 2024, up from $5.6 million in the same period last year, reflecting increased research and development expenses. Moreover, Tourmaline Bio secured gross proceeds of approximately $172.5 million from a public offering, bolstering its financial position to support ongoing and future operations. Looking forward, Tourmaline Bio management anticipates continued development progress, backed by a solid cash position and strategic partnerships, to advance its pipeline and achiev
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 [Yahoo! Finance]Yahoo! Finance
- Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024GlobeNewswire
- Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 [Yahoo! Finance]Yahoo! Finance
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at HC Wainwright from $48.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
TRML
Earnings
- 11/7/24 - Beat
TRML
Sec Filings
- 11/15/24 - Form EFFECT
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TRML's page on the SEC website